{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:27:58Z","timestamp":1767677278250,"version":"build-2065373602"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T00:00:00Z","timestamp":1250640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cytopathology"],"published-print":{"date-parts":[[2009,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Human papillomavirus (HPV) DNA testing using Hybrid Capture 2 assay with ThinPrep Papanicolaou (Pap) collection is the only US Food and Drug Administration\u2010approved method for the triage of women with atypical squamous cells of undetermined significance (ASCUS). Although SurePath Pap collection has been used for Hybrid Capture 2 HPV DNA testing, clinical validation of this method has been scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>From a cervical cancer\u2010screening program in Mississippi, we analyzed data from screenings of 8380 women with ASCUS Pap results who underwent reflex Hybrid Capture 2 HPV DNA tests during a course of 4 years. Of these, 4145 were screened with the ThinPrep collection system, and 4235 were screened with SurePath. Results of follow\u2010up biopsies within 3 months of Pap tests were available for the ThinPrep group (229 cases) and the SurePath group (455 cases). Hybrid Capture 2 positive rates and the follow\u2010up biopsy results from both groups were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Hybrid Capture 2 detected high\u2010risk HPV DNA in 68.8% of ThinPrep and 66.7% of SurePath\u2010collected specimens (<jats:italic>P<\/jats:italic> = .37). Detection rates for CIN2+ and CIN3+ were also comparable between ThinPrep (21.4%, 3.1%) and SurePath (15.4%, 4.2%) using Hybrid Capture 2 (<jats:italic>P<\/jats:italic> = .06, <jats:italic>P<\/jats:italic> = .45). In ThinPrep\u2010collected specimens, 4.4% were quantitatively insufficient for Hybrid Capture 2 testing. Significantly more equivocal Hybrid Capture 2 results were observed in SurePath (11.4%) than in ThinPrep specimens (3.2%). However, 67.4% of women with equivocal Hybrid Capture 2 results had negative 1\u2010year Pap cytology follow\u2010up in the SurePath group.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Hybrid Capture 2 positive rates and CIN2\u20103 detection rates were comparable for the SurePath and ThinPrep Pap collection systems, thus supporting the use of SurePath for Hybrid Capture 2 testing. Cancer (Cancer Cytopathol) 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncy.20043","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T16:33:10Z","timestamp":1250699590000},"page":"318-325","source":"Crossref","is-referenced-by-count":10,"title":["Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens"],"prefix":"10.1002","volume":"117","author":[{"given":"Anwer","family":"Siddiqi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Spataro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israh","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithra","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhyne","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.11.796"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc798"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.07.047"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000109426.82624.f8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1309\/BA43HMCAJ26VWQH3"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/93.4.293","article-title":"Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial","volume":"93","author":"Solomon D","year":"2001","journal-title":"J Natl Cancer Inst."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22285"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/PDM.0b013e31805c99ae"},{"issue":"3","key":"e_1_2_7_11_2","first-page":"S3\/78","article-title":"Chapter 9: Clinical applications of HPV testing: a summary of meta\u2010analyses","volume":"24","author":"Arbyn M","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/428779"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.8.813"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20009"}],"container-title":["Cancer Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncy.20043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.20043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:57:17Z","timestamp":1760306237000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncy.20043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10,25]]}},"alternative-id":["10.1002\/cncy.20043"],"URL":"https:\/\/doi.org\/10.1002\/cncy.20043","archive":["Portico"],"relation":{},"ISSN":["1934-662X","1934-6638"],"issn-type":[{"type":"print","value":"1934-662X"},{"type":"electronic","value":"1934-6638"}],"subject":[],"published":{"date-parts":[[2009,8,19]]}}}